
Round ’em up. The Presidential priorities that have everything and nothing to do with each other. This week has been a healthcare whirlwind. Here’s what I think you need to know * Most favored nation policy is still kicking around and the company announcements are interesting, but I want to poke around under the hood…

Some weeks it feels like this newsletter writes itself. This is not one of those weeks. Onward. Caught my Eye Medicaid Math. Kaiser Family Foundation has a terrific visual of how the One Big Beautiful Bill will impact the uninsured rate by state. Employer Math. Employers are expecting a big jump in premiums (9%, 7.6%…

I have a case of existential dread, and yet the world keeps spinning so let’s do this… Caught my Eye More Cowbell. Late last year I put out a report on biosimilars and it called out how the Inflation Reduction Act could hurt innovation and savings for biosimilars. Here is a report from Matrix Global…

Direct Cost. I’ve written about the cuts from the National Institutes of Health (NIH), but I’m not sure I was clear on the impact on pharmaceutical manufacturers. Pharma relies on basic research for its drugs, and they also rely on scientists that have been trained in graduate schools and post-doctoral fellowships to develop and advance…

In the DC area, with many family, friends and neighbors working for the federal government, these last few weeks have felt downright crappy. Furloughs, contracts being upended, fear about what’s next — all for people who love their jobs serving the public. It isn’t a fork in the road, it feels like a game of…